Have a feature idea you'd love to see implemented?
Let us know!
GNLX Genelux Corp
Price (delayed)
$2.46
Market cap
$84.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.95
Enterprise value
$80.9M
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product
Highlights
Genelux's quick ratio has soared by 80% YoY and by 6% from the previous quarter
The company's EPS rose by 29% YoY
GNLX's debt has surged by 53% year-on-year but it is down by 8% since the previous quarter
GNLX's equity is up by 38% YoY but it is down by 12% from the previous quarter
Genelux's revenue has shrunk by 97% YoY
GNLX's gross profit has dropped by 97% year-on-year
Key stats
What are the main financial stats of GNLX
Market
Valuations
Earnings
Shares outstanding
34.54M
Market cap
$84.96M
Enterprise value
$80.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.57
Price to sales (P/S)
10,618.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,112.62
Revenue
$8,000
EBIT
-$27.65M
EBITDA
-$26.88M
Free cash flow
-$24.36M
Per share
Balance sheet
Liquidity
EPS
-$0.95
Free cash flow per share
-$0.71
Book value per share
$0.96
Revenue per share
$0
TBVPS
$1.17
Total assets
$40.27M
Total liabilities
$7.18M
Debt
$2.04M
Equity
$33.09M
Working capital
$30.41M
Debt to equity
0.06
Current ratio
6.47
Quick ratio
6.13
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
-336,037.5%
Gross margin
100%
Net margin
-345,750%
Operating margin
-361,862.5%
Return on assets
-80.2%
Return on equity
-105.1%
Return on invested capital
-117.7%
Return on capital employed
-79.7%
Return on sales
-345,675%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GNLX stock price
How has the Genelux stock price performed over time
Intraday
-1.2%
1 week
-16.33%
1 month
-7.17%
1 year
-76.3%
YTD
-82.44%
QTD
3.8%
Financial performance
How have Genelux's revenue and profit performed over time
Revenue
$8,000
Gross profit
$8,000
Operating income
-$28.95M
Net income
-$27.66M
Gross margin
100%
Net margin
-345,750%
Genelux's revenue has shrunk by 97% YoY
GNLX's gross profit has dropped by 97% year-on-year
The company's operating income fell by 43% YoY and by 6% QoQ
The net income has contracted by 11% YoY and by 4.2% from the previous quarter
Growth
What is Genelux's growth rate over time
Valuation
What is Genelux stock price valuation
P/E
N/A
P/B
2.57
P/S
10,618.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,112.62
The company's EPS rose by 29% YoY
GNLX's price to book (P/B) is 70% lower than its last 4 quarters average of 8.6
GNLX's equity is up by 38% YoY but it is down by 12% from the previous quarter
Genelux's revenue has shrunk by 97% YoY
The price to sales (P/S) is 3.4% higher than the last 4 quarters average of 10265.2
Efficiency
How efficient is Genelux business performance
GNLX's ROE has soared by 86% YoY and by 4.7% from the previous quarter
Genelux's return on invested capital has increased by 33% QoQ
Genelux's return on assets has increased by 31% YoY
The company's return on sales fell by 4.2% QoQ
Dividends
What is GNLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GNLX.
Financial health
How did Genelux financials performed over time
The current ratio has soared by 82% year-on-year and by 8% since the previous quarter
Genelux's quick ratio has soared by 80% YoY and by 6% from the previous quarter
GNLX's debt is 94% smaller than its equity
GNLX's debt has surged by 53% year-on-year but it is down by 8% since the previous quarter
GNLX's equity is up by 38% YoY but it is down by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.